MedPath

Avextra Backs PsyPal: Landmark Psilocybin Therapy Study for Palliative Care

• Avextra is the industry partner in the PsyPal study, a Phase 2 clinical trial across four European countries, focusing on psilocybin-assisted therapy for palliative care patients with depression. • The PsyPal study, sponsored by the University Medical Center Groningen, involves 19 organizations from nine countries to address unmet needs in palliative care. • The trial will assess the safety and efficacy of psilocybin-assisted therapy to improve mental health and quality of life for patients with life-limiting diseases and their caregivers. • Avextra will supply the study drug and placebo, providing regulatory support, and aims to broaden patient access to innovative therapies, marking a milestone in their clinical journey.

Avextra AG is participating as an industry partner in the PsyPal study, a Horizon Europe EU-funded research project investigating psilocybin-assisted therapy. Scheduled to commence in 2025, this randomized controlled trial will explore psilocybin's potential in alleviating psychological distress in palliative care patients across Denmark, Portugal, the Netherlands, and Czechia. The study is sponsored by the University Medical Center Groningen in the Netherlands.
The PsyPal study marks a significant milestone in the field, initiated by a pan-European consortium of clinical sites, universities, companies, and non-profits. Avextra will supply the study drug and placebo, offering regulatory support throughout the submission process. The company aims to support psilocybin therapy for palliative care, working towards Marketing Authorization (MA) to broaden patient access.

Study Focus and Design

PsyPal is designed to evaluate the safety, efficacy, and long-term impact of psilocybin therapy for non-oncology palliative care patients. The trial will focus on individuals suffering from chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and atypical Parkinson’s disease (APD). The study will also explore patient access models and assess the therapy's impact on caregivers.
The multidisciplinary consortium includes 19 organizations from nine countries and is coordinated by the University Medical Centre Groningen, in partnership with HumanKindLabs. Ulf Bremberg, CEO of HumanKindLabs, stated, "This study is a testament to what’s possible when academia, industry, and patient advocates unite for a common cause. Together, we’re creating a holistic approach that addresses depression and distress in palliative care in a comprehensive way."

Avextra's Perspective

Bernhard Babel, CEO of Avextra, commented, "For Avextra, PsyPal is not a one-off but an additional milestone of our clinical journey. We are paving the way for a future where psychoactive plant-based substances seamlessly integrate into evidence-based mainstream health care."

Correction

An earlier press release mentioned EU and EMA approval. The study is authorized with conditions according to the Clinical Trials Regulation (CTR).
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

PEARLDIVER: Europe-Wide Platform Trial Aims to Accelerate Depression Treatment Development

The PEARLDIVER project, a Europe-wide platform study, will evaluate multiple depression treatments simultaneously using a shared infrastructure.
Initially focusing on repurposed drugs, the trial aims to expedite the identification of effective therapies for individual patients.

Psyence Biomed Advances Phase IIb Psilocybin Trial for Adjustment Disorder in Palliative Care

Psyence Biomed's Phase IIb trial of psilocybin for Adjustment Disorder in palliative care has activated two Australian sites and commenced patient screening.
The company anticipates randomizing the first patients into the study in January, with therapist training ongoing at the active sites.

SynAct Pharma's Resomelagon Receives EU Trial Approval for Phase 2b Rheumatoid Arthritis Study

SynAct Pharma received EU approval for its Phase 2b ADVANCE study of resomelagon (AP1189) in newly diagnosed severe rheumatoid arthritis (RA) patients.
The ADVANCE study will evaluate three doses of resomelagon versus placebo, in combination with methotrexate, as a first-line RA treatment.

Study Estimates Millions Could Benefit from Psilocybin Treatment for Depression

An Emory University study estimates that over 5 million Americans with depression could benefit from psilocybin-assisted therapy, highlighting its potential impact.
Psilocybin has received breakthrough designation from the FDA, expediting the review of Phase III clinical trial results due to its therapeutic potential for depression.

Psyence Group Expands Psilocybin Clinical Trials for Adjustment Disorder in Palliative Care

Psyence Biomedical has added Empax Center in Australia as a second site for its Phase IIb clinical trial of psilocybin-based treatments for Adjustment Disorder.
The trial anticipates commencing patient treatments imminently, with the first subject expected to be enrolled in early December.

Psyence Biomedical Expands Phase IIb Psilocybin Trial for Adjustment Disorder in Palliative Care

Psyence Biomedical has recruited Empax Center in Perth, Australia, as the second clinical trial site for its Phase IIb study of nature-derived psilocybin.
The trial investigates psilocybin as a potential treatment for Adjustment Disorder in patients receiving palliative care.

Psyence Biomed Expands Phase IIb Psilocybin Trial for Adjustment Disorder in Palliative Care

Psyence Biomed adds Empax Center in Perth, Australia, as the second clinical trial site for its Phase IIb study on nature-derived psilocybin.
The trial investigates psilocybin as a potential treatment for Adjustment Disorder in palliative care patients.

Lykos Therapeutics' MDMA Therapy for PTSD Faces Potential VA Funding and Third-Party Data Review

Lykos Therapeutics is exploring the possibility of securing funding from the Department of Veterans Affairs (VA) for its Phase 3 clinical trials of MDMA-assisted therapy for PTSD.
As part of its path to FDA approval, Lykos Therapeutics may undergo a third-party review of its Phase 3 data, ensuring an objective assessment of the therapy's efficacy and safety.

Psychedelic Therapies Approach Europe Amidst Regulatory and Access Challenges

Psychedelic therapies, including psilocybin and MDMA, are gaining traction in Europe for treating mental health conditions like depression and addiction.
Clinical trials are underway across Europe, with Compass Pathways leading the way in testing psilocybin for treatment-resistant depression.

Autobahn Therapeutics Initiates Phase 2 Trial of ABX-002 for Major Depressive Disorder

Autobahn Therapeutics has commenced the AMPLIFY Phase 2 trial to evaluate ABX-002 as an adjunctive treatment for major depressive disorder (MDD).
The trial will enroll 230 adults with moderate-to-severe depression to assess the safety, tolerability, efficacy, and pharmacodynamic effects of ABX-002.

Reference News

[1]
Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care - Morningstar
morningstar.com · Dec 20, 2024

Avextra partners in PsyPal, a Horizon Europe-funded study on psilocybin-assisted therapy for palliative care patients, s...

[2]
Avextra Supports First Fully EU-Funded Psilocybin Therapy - GlobeNewswire
globenewswire.com · Dec 12, 2024

Avextra leads EU-funded PsyPal project, a Phase II study on psilocybin-assisted therapy for palliative care patients wit...

[3]
Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care
globenewswire.com · Dec 21, 2024

Avextra partners in PsyPal, a Horizon Europe-funded Phase 2 trial examining psilocybin-assisted therapy for palliative c...

[4]
Press Release: Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care
finanznachrichten.de · Dec 20, 2024

Avextra partners in PsyPal, a Phase 2 trial examining psilocybin therapy for palliative care patients across Europe, aim...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy